OTC Stock Picks Newsletter Is Putting a Close Watch This Week on ERBB, ACTC

Stamford, CT -- (SBWIRE) -- 01/07/2013 -- Tranzbyte Corp. ERBB closed out last Friday at .004 for a 73.91% gain for the week. It looks like a new interest came back into the stock last week. The company released an interview with the Founder, Brian Cook last week which gives us the feeling more exciting updates are coming in the near future. OTC Stock Picks will continue updating trading activity and news updates on the company through 2013. The interview can be heard here http://voicerussia.com/radio_broadcast/61124198/99589801.html

About Tranzbyte Corp. (ERBB) About Tranzbyte Corp.
(ERBB)The Tranzbyte Corporation (http://www.tranzbyte.com) is a driving force behind Altitude Organic Corporation and ProximaRF. The company continues its plan to acquire, hold, or spin out successful divisions in what has been described in previous news releases as "dividend farming." Companies that qualify that decide to become public on their own will agree to carve out shares for Tranzbyte and their ERBB shareholders once the spin-out is registered and publicly trading. This year, Tranzbyte acquired ProximaRF – a leading-edge company that produces a line of products supporting leading-edge RFID technology.

Tranzbyte also houses the company's 9-year-old technology division which is actively engaged in the marketing and sale of its optical media enhancement products to potential customers in the US and Asia. Products in the Tranzbyte division include FLASHAlbum™ and FlixStix -- technologies that enable distributors of optical media (CDs, DVDs, etc.) to consolidate the best features of each medium onto a single content-protected USB flash drive.

Click here for a free analysis report on ERBB http://otcstockpicks.net/

Advanced Cell Technology (ACTC) Closed the week at .0799 for a 47.96% gain to end last weeks trading session. Advanced Cell Technology is a leader in the field of regenerative medicine. Robert Lanza, M.D., chief scientific officer of ACT. recently stated “They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets don’t contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013.” OTC Stock Picks will be following ACTC very closely through 2013

About Advanced Cell Technology (ACTC)
is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.

Click here to get a free analysis report for ACTC http://otcstockpicks.net/

About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.

Disclaimer
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.